Literature DB >> 7899229

Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs.

W F Elmquist1, K K Chan, R J Sawchuk.   

Abstract

The synovial mean transit time of diclofenac was determined by two methods from existing plasma and synovial fluid concentration-time data. These data were obtained from single- and multiple-dosing regimens of diclofenac in patients with osteoarthritis and rheumatoid arthritis. Plasma and synovial fluid concentration-time data taken from the literature for four other nonsteroidal antiinflammatory drugs (etodolac, ibuprofen, indomethacin, and tenoxicam) were also analyzed. The two methods of data analysis rely on the determination of the ratio of the area under the synovial fluid concentration-time curve to the area under the plasma concentration-time curve. Both methods can be considered noncompartmental because in determining the first-order exit rate constant for the synovial fluid (the inverse of the synovial mean transit time), an analysis of the overall distribution and elimination characteristics of the drug is unnecessary. Method 1 makes use of the information contained in the postdistributional synovial fluid to plasma concentration ratio whereas method 2 is a linear pharmacokinetic model using a partial-areas analysis. The single dose mean +/- S.D. synovial fluid exit rate constant for diclofenac was 0.39 +/- 0.33 hr-1 (n = 6), which was not significantly different from that determined by method 2; which was 0.49 +/- 0.52 hr-1. The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7899229     DOI: 10.1023/a:1018994712387

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

1.  Stereoselective disposition of ibuprofen enantiomers in synovial fluid.

Authors:  R O Day; K M Williams; G G Graham; E J Lee; R D Knihinicki; G D Champion
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

2.  The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis.

Authors:  M Kraml; D R Hicks; M McKean; J Panagides; D Furst; J Furst
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

3.  Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio.

Authors:  P H Hinderling; D Hartmann; C Crevoisier; U Moser; P Heizmann
Journal:  Ther Drug Monit       Date:  1988       Impact factor: 3.681

4.  Estimation of average times of residence, recycle and interconversion of blood-borne compounds using tracer methods.

Authors:  A Rescigno; E Gurpide
Journal:  J Clin Endocrinol Metab       Date:  1973-02       Impact factor: 5.958

5.  Methotrexate pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick; D S Zaharko; J A Longstreth
Journal:  J Pharm Sci       Date:  1971-08       Impact factor: 3.534

6.  Synovial fluid concentrations of diclofenac in patients with rheumatoid arthritis or osteoarthritis.

Authors:  M D Benson; M Aldo-Benson; K D Brandt
Journal:  Semin Arthritis Rheum       Date:  1985-11       Impact factor: 5.532

7.  Fitting straight lines when both variables are subject to error.

Authors:  D S Riggs; J A Guarnieri; S Addelman
Journal:  Life Sci       Date:  1978 Apr 3-17       Impact factor: 5.037

8.  Diclofenac sodium (GP 45840, Voltaren), a potent inhibitor of prostaglandin synthetase.

Authors:  E C Ku; J M Wasvary; W D Cash
Journal:  Biochem Pharmacol       Date:  1975-03-01       Impact factor: 5.858

9.  Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets.

Authors:  C Y Lui; R Oberle; D Fleisher; G L Amidon
Journal:  J Pharm Sci       Date:  1986-05       Impact factor: 3.534

10.  Osmosin: its effect on plasma and synovial fluid kinetics of indomethacin.

Authors:  P D Fowler; P T Dawes
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more
  7 in total

Review 1.  Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid.

Authors:  R O Day; A J McLachlan; G G Graham; K M Williams
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

Review 3.  Using pharmacokinetic principles to optimize pain therapy.

Authors:  Kay Brune; Bertold Renner; Burkhard Hinz
Journal:  Nat Rev Rheumatol       Date:  2010-09-07       Impact factor: 20.543

4.  Development of a dog microdialysis model for determining synovial fluid pharmacokinetics of anti-arthritis compounds exemplified by methotrexate.

Authors:  Mingxin Qian; Wanda West; Jing-Tao Wu; Bing Lu; David D Christ
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

5.  Penetration of topical diclofenac sodium 4 % spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trial.

Authors:  Turgay Efe; Ercan Sagnak; Philip P Roessler; Alan Getgood; Thilo Patzer; Susanne Fuchs-Winkelmann; Christian D Peterlein; Markus D Schofer
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-01-22       Impact factor: 4.342

6.  In vitro-in vivo correlation on delivery of drug candidates to articular cartilage.

Authors:  Qin Wang; Sonya Glasson; Uma Raut; Jamie Emerson; Tracey Blanchet; Gary Bridson; Richard Sheldon; Nevena Mollova; Elisabeth Morris; Xin Xu; Vikram S Patel
Journal:  Pharm Res       Date:  2008-03-07       Impact factor: 4.200

Review 7.  Biomaterial strategies for improved intra-articular drug delivery.

Authors:  Lina M Mancipe Castro; Andrés J García; Robert E Guldberg
Journal:  J Biomed Mater Res A       Date:  2020-08-24       Impact factor: 4.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.